The effects of a new angiotensin converting enzyme inhibitor, delapril hydrochloride, (delapril) on renal function, and the renin-angiotensin-aldosterone and kallikrein-kinin prostagrandin systems were studied in 10 hypertensive patients. After 4 to 12 months (7.6±0.9 ‹SE›) of treatment with 15-60 mg/day (36±6.8) of delapril (b. i. d.), mean arterial pressure was decreased from 126±3.0 to 110±4.4 mmHg (p<0.01). Although renal blood flow (RBF), assessed by PAH clearance and hematocrit, was increased from 437±51 to 490±49 ml/min (p<0.05) and renal vascular resistance was decreased (p<0.05), glomerular filtration rate, measured by endogenous creatinine clearance, did not change significantly. Thus, filtration fraction was reduced (p<0.01). Plasma renin activity was increased from 1.5±0.3 to 4.4±1.1 ng/ml/hr (p<0.01). Plasma aldosterone concentration tended to decrease (p<0.1), and urinary aldosterone excretion showed on significant change. Although urinary kallikrein and prostagrandin E2 excretions were increased (p<0.05), urinary throm boxane B
2 excretions was reduced (p<0.05). In addition, the changes in RBF were significantly correlated with those in urinary PGE
2 excretion (r=0.63, p<0.05). These results suggest that the antihypertensive effect of delapril is multifactorial and that the improvement of RBF seen during delapril administration in the present study may be partly due to the suppression of the renin-angiotensin-aldosterone system and the activation of kallikrein-kinin-prostagrandin system.
View full abstract